At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 53 enrolled
Drug / intervention
BPZE1 +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2b, Placebo-Controlled, Randomized Study of BPZE1 Intranasal Pertussis Vaccine in Healthy Adults to Assess Protection Against Colonization Following Challenge With Virulent Wild-Type Bordetella Pertussis
In Brief
A Phase 2 clinical trial evaluating BPZE1, Placebo, and 2 other interventions for Pertussis/Whooping Cough and Bordetella Pertussis, Whooping Cough. Completed, enrolled 53 participants across 2 sites.
Detailed Summary
This is a randomised, double-blinded, placebo-controlled trial of BPZE1 that includes virulent B. pertussis challenge followed by a safety follow-up.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
Enrollment StartJun 2022
First PostedJul 2022
Primary CompletionJul 2023
Study CompletionOct 2023
TodayJul 2026
First PostedJul 15, 2022
Enrollment StartJun 20, 2022
Primary CompletionJul 25, 2023
Study CompletionOct 26, 2023
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 4.0 years ago
Interventions
BPZE1biological
Live attenuated vaccine
Placebobiological
Placebo
Azithromycindrug
Antibiotic
Bordetella Pertussis Challenge Strainother
Challenge Strain